Literature DB >> 7908605

Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms.

K Z Bezchlibnyk-Butler1, G J Remington.   

Abstract

Most patients on neuroleptic therapy experience extrapyramidal symptoms in one form or another during treatment. While the risk of extrapyramidal symptoms appears diminished with the newer and "atypical" neuroleptics (for example, risperidone, remoxipride, clozapine), it is not eliminated. It is essential that the treating clinician monitor for such side effects since if they are left untreated they can be an ongoing source of discomfort to the patient and may affect compliance with therapy. Antiparkinsonian medication represents the mainstay of treatment for neuroleptic-induced extrapyramidal symptoms. Their clinical use is reviewed here with reference to mode of action, indications, choice, side-effects and precautions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908605     DOI: 10.1177/070674379403900203

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  6 in total

1.  Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats.

Authors:  Keita Ishiwari; Lisa J Madson; Andrew M Farrar; Susana M Mingote; John P Valenta; Michael D DiGianvittorio; Lauren E Frank; Merce Correa; Jörg Hockemeyer; Christa Müller; John D Salamone
Journal:  Behav Brain Res       Date:  2006-12-21       Impact factor: 3.332

Review 2.  The Canadian experience with risperidone for the treatment of schizophrenia: an overview.

Authors:  M Iskedjian; M Hux; G J Remington
Journal:  J Psychiatry Neurosci       Date:  1998-09       Impact factor: 6.186

Review 3.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

4.  Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics.

Authors:  Hikaru Hori; Norio Yasui-Furukori; Naomi Hasegawa; Jun-Ichi Iga; Shinichiro Ochi; Kayo Ichihashi; Ryuji Furihata; Yoshitaka Kyo; Yoshikazu Takaesu; Takashi Tsuboi; Fumitoshi Kodaka; Toshiaki Onitsuka; Tsuyoshi Okada; Atsunobu Murata; Hiroko Kashiwagi; Hitoshi Iida; Naoki Hashimoto; Kazutaka Ohi; Hisashi Yamada; Kazuyoshi Ogasawara; Yuka Yasuda; Hiroyuki Muraoka; Masahide Usami; Shusuke Numata; Masahiro Takeshima; Hirotaka Yamagata; Tatsuya Nagasawa; Hiromi Tagata; Manabu Makinodan; Mikio Kido; Eiichi Katsumoto; Hiroshi Komatsu; Junya Matsumoto; Chika Kubota; Kenichiro Miura; Akitoyo Hishimoto; Koichiro Watanabe; Ken Inada; Hiroaki Kawasaki; Ryota Hashimoto
Journal:  Front Psychiatry       Date:  2022-05-17       Impact factor: 5.435

Review 5.  Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism.

Authors:  John D Salamone; Keita Ishiwari; Adrienne J Betz; Andrew M Farrar; Susana M Mingote; Laura Font; Jörg Hockemeyer; Christa E Müller; Mercè Correa
Journal:  Parkinsonism Relat Disord       Date:  2008-06-27       Impact factor: 4.891

6.  The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors.

Authors:  Adrienne J Betz; Peter J McLaughlin; Melissa Burgos; Suzanne M Weber; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2007-06-27       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.